MedTrace Logo

Trident II Tritanium Acetabular Shell Outcomes Study

NCT02999009 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 383

Last updated 2026-04-01

No results posted yet for this study

Summary

The purpose of this study is to review the performance and success rate of an FDA approved cementless hip replacement part called the Trident II Tritanium Acetabular Shell. The study will specifically look at the need to revise the hip replacement after 5 years. This will be compared to how much this happens in patients who have hip replacement with similar cementless acetabular shells.

Conditions

  • Arthroplasty, Replacement, Hip

Interventions

DEVICE

Trident II Tritanium Acetabular Shell

A hemispherical acetabular shell indicated for cementless application.

Sponsors & Collaborators

  • Stryker Orthopaedics

    lead INDUSTRY

Principal Investigators

  • Kevin Barga · Director, Clinical Research - Stryker Joint Replacement

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-20
Primary Completion
2026-06-30
Completion
2031-03-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02999009 on ClinicalTrials.gov